SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/649D815D3DF8DEEBDDC69C9AB9E522F0350EF09584501ABB393804DAF528DC90AD0365F1DB6E4F68B0A6B376F0FA68F7>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/649D815D3DF8DEEBDDC69C9AB9E522F0350EF09584501ABB393804DAF528DC90AD0365F1DB6E4F68B0A6B376F0FA68F7
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/649D815D3DF8DEEBDDC69C9AB9E522F0350EF09584501ABB393804DAF528DC90AD0365F1DB6E4F68B0A6B376F0FA68F7
http://www.w3.org/2000/01/rdf-schema#comment
"MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma."
xsd:string
http://purl.uniprot.org/uniprot/#_B067A964AAFDA494BB31A04CAA5E16CB74B9346F7C8C5F9B7640ABC4EFDB8B8294E5ACD35EA4A24A3A7361C282E054FB
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/649D815D3DF8DEEBDDC69C9AB9E522F0350EF09584501ABB393804DAF528DC90AD0365F1DB6E4F68B0A6B376F0FA68F7
http://purl.uniprot.org/uniprot/B4DHE8
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/649D815D3DF8DEEBDDC69C9AB9E522F0350EF09584501ABB393804DAF528DC90AD0365F1DB6E4F68B0A6B376F0FA68F7
http://purl.uniprot.org/uniprot/#_B4DHE8-mappedCitation-34145929
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/649D815D3DF8DEEBDDC69C9AB9E522F0350EF09584501ABB393804DAF528DC90AD0365F1DB6E4F68B0A6B376F0FA68F7